Biosimilar pegfilgrastim: Phase I started

Infarco’s Cinfa Biotech subsidiary began a double-blind, crossover, German Phase I trial to compare subcutaneous B12019 vs. subcutaneous Neulasta pegfilgrastim in about 96 healthy volunteers. ...